Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy�…

Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is�…

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As�…

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features�…

Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of�…

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large�…

In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny�…

Immune checkpoint inhibitor (ICI) therapy is effective against many cancers for a subset of
patients; a large percentage of patients remain unresponsive to this therapy. One�…

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer�…

A new mode of cell death, disulfidptosis, has been discovered. Clinical prognostic
significance of disulfidptosis related pattern in hepatocellular carcinoma (HCC). In this study�…